Teradan Clinical Trials
Welcome,         Profile    Billing    Logout  
 5 Trials 
26 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Powell, Richard J
NCT04511702: Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate

Completed
4
191
US
Pegloticase with MTX, Methotrexate
Amgen
Chronic Uncontrolled Gout, Gout, Uncontrolled Gout
01/24
03/24
NCT06015282: The Celljuvant Study: a Phase 3 Immunogenicity and Safety Study of AQIVc Vaccine in Adults Aged 50 Years and Older

Active, not recruiting
3
7741
Europe, Canada, US, RoW
Investigational aQIVc, licensed QIV1, licensed QIV2
Seqirus
Influenza, Human
03/24
01/25
SUVN-G3031, NCT04072380: A Study to Evaluate Safety, and Efficacy of (Samelisant) in Patients With Narcolepsy With and Without Cataplexy

Completed
2
190
Canada, US
SUVN-G3031, Samelisant, Placebo
Suven Life Sciences Limited
Narcolepsy
06/23
06/23
NCT05853380: A Multi-Center Prospective Open Label Study of a Web-based Application for Pulse Rate in Adult Patients

Completed
N/A
85
US
Informed Vital Core App
Mindset Medical
Vital Sign Evaluation
06/23
06/23
ROADSTER 3, NCT05365490: Post-approval Study of Transcarotid Artery Revascularization in Standard Risk Patients with Significant Carotid Artery Disease

Active, not recruiting
N/A
344
US
Transcarotid Artery Revascularization (TCAR), Carotid Revascularization, Carotid Artery Stenting
Silk Road Medical
Carotid Artery Diseases
09/25
09/25
Lorch, Daniel
SURMOUNT-OSA, NCT05412004: Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

Completed
3
469
Europe, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Sleep Apnea, Obesity
03/24
03/24
TRIUMPH-1, NCT05929066: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

Active, not recruiting
3
2300
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea
04/26
05/26
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Active, not recruiting
3
1000
Europe, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
05/26
05/26
REPOSA, NCT06146101: RePOSA-Revealing the Efficacy of IHL-42X Use in Patients with OSA

Recruiting
2/3
560
US
IHL-42X Low Dose, Phase 2 Investigational Product - IHL-42X Low dose, IHL-42X High Dose, Phase 2 Investigational Product - IHL-42X High dose, Placebo, Phase 2 Placebo, IHL-42X (Optimal Dose), Phase 3 Investigational Product - IHL-42X, Dronabinol, Phase 3 Comparator - Reference Listed Drug/Dronabinol, Acetazolamide, Phase 3 Comparator - Reference Listed Drug/Acetazolamide, Phase 3 Placebo
Incannex Healthcare Ltd
Obstructive Sleep Apnea
12/26
12/26
NCT04905836: Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress

Recruiting
2
60
US
COVI-MSC, Placebo
Sorrento Therapeutics, Inc.
Covid19
12/22
03/23
SUVN-G3031, NCT04072380: A Study to Evaluate Safety, and Efficacy of (Samelisant) in Patients With Narcolepsy With and Without Cataplexy

Completed
2
190
Canada, US
SUVN-G3031, Samelisant, Placebo
Suven Life Sciences Limited
Narcolepsy
06/23
06/23
NCT05936151: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Recruiting
2
120
Europe, Canada, US
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Overweight or Obesity, CKD, Type 2 Diabetes
11/25
11/25
Royal, Mike
NCT04905836: Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress

Recruiting
2
60
US
COVI-MSC, Placebo
Sorrento Therapeutics, Inc.
Covid19
12/22
03/23
NCT04885972: Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis

Active, not recruiting
2
124
US
Resiniferatoxin, RTX, Zilretta, triamcinolone acetonide, Placebo
Sorrento Therapeutics, Inc.
Osteoarthritis, Knee, Knee Osteoarthritis, Knee Pain Chronic
09/23
11/23
NCT05067257: Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer

Suspended
2
120
US
Resiniferatoxin, RTX, Placebo
Sorrento Therapeutics, Inc.
Pain, Intractable, Pain Cancer, Pain
06/27
12/27
NCT04992247: Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise

Withdrawn
2
60
NA
COVI-MSC, Placebo
Sorrento Therapeutics, Inc.
Covid19
07/24
09/24
Maverick, NCT05361915: Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer

Suspended
2
100
US
Abivertinib, STI-5656, Abiraterone
Sorrento Therapeutics, Inc.
Prostate Cancer, Prostate Cancer Metastatic
01/28
01/28
NCT04559412: Study to Assess the Safety and Efficacy of Enbrel Administered by Sofusa DoseConnect for Rheumatoid Arthritis

Active, not recruiting
1b
11
US
Sofusa DoseConnect, sofusa, Enbrel
Sorrento Therapeutics, Inc.
Rheumatoid Arthritis
01/24
12/24
NCT05007418: Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

Recruiting
1b
54
US
STI-1492
Sorrento Therapeutics, Inc.
Multiple Myeloma
12/25
02/26
OV2-RRST-101, NCT05361954: Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors

Not yet recruiting
1b
36
NA
STI-1386, Seprehvec
Sorrento Therapeutics, Inc.
Cancer, Cancer of Pancreas, Sarcoma, Hepatic Metastasis, Solid Tumor
10/26
02/27
NCT04900519: Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors

Recruiting
1
100
US
STI-6643
Sorrento Therapeutics, Inc.
Solid Tumor, Relapsed Solid Neoplasm, Refractory Tumor
12/24
03/25
NCT05472649: Long-Term Follow-Up of Patients Who Received Gene-Modified Cell Therapy

Enrolling by invitation
N/A
1
US
Gene-Modified Cell Therapy
Sorrento Therapeutics, Inc.
Long-term Follow-up
12/36
05/37
Fitzwater, Don
SUVN-G3031, NCT04072380: A Study to Evaluate Safety, and Efficacy of (Samelisant) in Patients With Narcolepsy With and Without Cataplexy

Completed
2
190
Canada, US
SUVN-G3031, Samelisant, Placebo
Suven Life Sciences Limited
Narcolepsy
06/23
06/23
Payne, Charles
SUVN-G3031, NCT04072380: A Study to Evaluate Safety, and Efficacy of (Samelisant) in Patients With Narcolepsy With and Without Cataplexy

Completed
2
190
Canada, US
SUVN-G3031, Samelisant, Placebo
Suven Life Sciences Limited
Narcolepsy
06/23
06/23
Poli, Francoise
SUVN-G3031, NCT04072380: A Study to Evaluate Safety, and Efficacy of (Samelisant) in Patients With Narcolepsy With and Without Cataplexy

Completed
2
190
Canada, US
SUVN-G3031, Samelisant, Placebo
Suven Life Sciences Limited
Narcolepsy
06/23
06/23
Poli, Fran
REPOSA, NCT06146101: RePOSA-Revealing the Efficacy of IHL-42X Use in Patients with OSA

Recruiting
2/3
560
US
IHL-42X Low Dose, Phase 2 Investigational Product - IHL-42X Low dose, IHL-42X High Dose, Phase 2 Investigational Product - IHL-42X High dose, Placebo, Phase 2 Placebo, IHL-42X (Optimal Dose), Phase 3 Investigational Product - IHL-42X, Dronabinol, Phase 3 Comparator - Reference Listed Drug/Dronabinol, Acetazolamide, Phase 3 Comparator - Reference Listed Drug/Acetazolamide, Phase 3 Placebo
Incannex Healthcare Ltd
Obstructive Sleep Apnea
12/26
12/26

Download Options